Lead Product(s): Efmoroctocog alfa
Therapeutic Area: Genetic Disease Product Name: Elocta
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: National Health Service (NHS)
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement June 29, 2020
The National Health Service (NHS) and Sobi UK have come to an agreement that will give people living with haemophilia A in the UK increased access to Elocta (efmoroctocog alfa), by lifting prior volume restrictions for the drug.